The following questions and topics will be covered in this presentation.
- Which of the following are barriers to prescribing buprenorphine? (select all)
A. Patient hesitancy due to misinformation about buprenorphine
B. Lack of prescriber knowledge about buprenorphine dosing, including conversion from full agonist opioids
C. Provider hesitancy due to higher risk of side effects vs full agonist opioids
D. Variability in product availability at retail pharmacies
- Which of the following interdisciplinary team members have a role in safely initiating and maintaining a patient on buprenorphine? (select all)
A. Pharmacist
B. Chaplain
C. Physician/APP
D. RN
E. Social worker
- Which of the following would be the most appropriate buprenorphine product for an elderly, opioid-naive patient, assuming he/she could get any formulation? (select all)
A. Buprenorphine/naloxone sublingual film (Suboxone(R))
B. Buprenorphine transdermal patch (Butrans)
C. Buprenorphine buccal film (Belbuca)
D. Buprenorphine sublingual tablet (Subutex)
- Which of the following are key educational points for patients who are hesitant to use buprenorphine products? (select all)
A. While buprenorphine is used in patients with a history of opioid addiction, it can be safely used in individuals with chronic pain and no history of addiction.
B. Buprenorphine has a favorable safety profile compared with other opioids.
C. Buprenorphine products are usually less expensive than other opioids.
D. Buprenorphine can only be prescribed by certain doctors in the United States.
- Which of the following protocols may be beneficial within a pain management or palliative care practice for buprenorphine prescribing? (select all)
A. Rotation from a full agonist
B. Initiation in an opioid-naïve patient
C. Titration of various buprenorphine products
D. Conversion to and from different buprenorphine products
E. Type of breakthrough medication used (buprenorphine product vs. full agonist)
